Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities

Erin E. Talbert, Jennifer Yang, Thomas A. Mace, Matthew R. Farren, Alton B. Farris, Gregory S. Young, Omar Elnaggar, Zheng Che, Cynthia D. Timmers, Priyani Rajasekera, Jennifer M. Maskarinec, Mark Bloomston, Tanios Bekaii-Saab, Denis C. Guttridge, Gregory B. Lesinski

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Involuntary weight loss, a part of the cachexia syndrome, is a debilitating comorbidity of cancer and currently has no treatment options. Results from a recent clinical trial at our institution showed that biliary tract cancer patients treated with a MEK inhibitor exhibited poor tumor responses but surprisingly gained weight and increased their skeletal muscle mass. This implied that MEKinhibition might be anticachectic. To test this potential effect of MEK inhibition, we utilized the established Colon-26 model of cancer cachexia and the MEK1/2 inhibitor MEK162. Results showed that MEK inhibition effectively prevented muscle wasting. Importantly, MEK162 retained its ability to spare muscle loss even in mice bearing a Colon-26 clone resistant to the MEK inhibitor, demonstrating that the effects of blocking MEK are at least in part independent of the tumor. Because single-agent MEK inhibitors have been limited as a first-line targeted therapy due to compensatory activation of other oncogenic signaling pathways, we combined MEK162 with the PI3K/Akt inhibitor buparlisib. Results showed that this combinatorial treatment significantly reduced tumor growth due to a direct activity on Colon-26 tumor cells in vitro and in vivo, while also preserving skeletal muscle mass. Together, our results suggest that as a monotherapy, MEK inhibition preserves muscle mass, but when combined with a PI3K/ Akt inhibitor exhibits potent antitumor activity. Thus, combinatorial therapy might serve as a new approach for the treatment of cancer cachexia.

Original languageEnglish (US)
Pages (from-to)344-356
Number of pages13
JournalMolecular Cancer Therapeutics
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Cachexia
Mitogen-Activated Protein Kinase Kinases
Phosphatidylinositol 3-Kinases
Neoplasms
Colon
Muscles
Skeletal Muscle
Biliary Tract Neoplasms
Therapeutics
Comorbidity
Weight Loss
Clone Cells
Clinical Trials
Weights and Measures
Growth
MEK162

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Talbert, E. E., Yang, J., Mace, T. A., Farren, M. R., Farris, A. B., Young, G. S., ... Lesinski, G. B. (2017). Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities. Molecular Cancer Therapeutics, 16(2), 344-356. https://doi.org/10.1158/1535-7163.MCT-16-0337

Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities. / Talbert, Erin E.; Yang, Jennifer; Mace, Thomas A.; Farren, Matthew R.; Farris, Alton B.; Young, Gregory S.; Elnaggar, Omar; Che, Zheng; Timmers, Cynthia D.; Rajasekera, Priyani; Maskarinec, Jennifer M.; Bloomston, Mark; Bekaii-Saab, Tanios; Guttridge, Denis C.; Lesinski, Gregory B.

In: Molecular Cancer Therapeutics, Vol. 16, No. 2, 01.02.2017, p. 344-356.

Research output: Contribution to journalArticle

Talbert, EE, Yang, J, Mace, TA, Farren, MR, Farris, AB, Young, GS, Elnaggar, O, Che, Z, Timmers, CD, Rajasekera, P, Maskarinec, JM, Bloomston, M, Bekaii-Saab, T, Guttridge, DC & Lesinski, GB 2017, 'Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities', Molecular Cancer Therapeutics, vol. 16, no. 2, pp. 344-356. https://doi.org/10.1158/1535-7163.MCT-16-0337
Talbert, Erin E. ; Yang, Jennifer ; Mace, Thomas A. ; Farren, Matthew R. ; Farris, Alton B. ; Young, Gregory S. ; Elnaggar, Omar ; Che, Zheng ; Timmers, Cynthia D. ; Rajasekera, Priyani ; Maskarinec, Jennifer M. ; Bloomston, Mark ; Bekaii-Saab, Tanios ; Guttridge, Denis C. ; Lesinski, Gregory B. / Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 2. pp. 344-356.
@article{5a672cd0d4444c288d3ef76f9a498055,
title = "Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities",
abstract = "Involuntary weight loss, a part of the cachexia syndrome, is a debilitating comorbidity of cancer and currently has no treatment options. Results from a recent clinical trial at our institution showed that biliary tract cancer patients treated with a MEK inhibitor exhibited poor tumor responses but surprisingly gained weight and increased their skeletal muscle mass. This implied that MEKinhibition might be anticachectic. To test this potential effect of MEK inhibition, we utilized the established Colon-26 model of cancer cachexia and the MEK1/2 inhibitor MEK162. Results showed that MEK inhibition effectively prevented muscle wasting. Importantly, MEK162 retained its ability to spare muscle loss even in mice bearing a Colon-26 clone resistant to the MEK inhibitor, demonstrating that the effects of blocking MEK are at least in part independent of the tumor. Because single-agent MEK inhibitors have been limited as a first-line targeted therapy due to compensatory activation of other oncogenic signaling pathways, we combined MEK162 with the PI3K/Akt inhibitor buparlisib. Results showed that this combinatorial treatment significantly reduced tumor growth due to a direct activity on Colon-26 tumor cells in vitro and in vivo, while also preserving skeletal muscle mass. Together, our results suggest that as a monotherapy, MEK inhibition preserves muscle mass, but when combined with a PI3K/ Akt inhibitor exhibits potent antitumor activity. Thus, combinatorial therapy might serve as a new approach for the treatment of cancer cachexia.",
author = "Talbert, {Erin E.} and Jennifer Yang and Mace, {Thomas A.} and Farren, {Matthew R.} and Farris, {Alton B.} and Young, {Gregory S.} and Omar Elnaggar and Zheng Che and Timmers, {Cynthia D.} and Priyani Rajasekera and Maskarinec, {Jennifer M.} and Mark Bloomston and Tanios Bekaii-Saab and Guttridge, {Denis C.} and Lesinski, {Gregory B.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1158/1535-7163.MCT-16-0337",
language = "English (US)",
volume = "16",
pages = "344--356",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities

AU - Talbert, Erin E.

AU - Yang, Jennifer

AU - Mace, Thomas A.

AU - Farren, Matthew R.

AU - Farris, Alton B.

AU - Young, Gregory S.

AU - Elnaggar, Omar

AU - Che, Zheng

AU - Timmers, Cynthia D.

AU - Rajasekera, Priyani

AU - Maskarinec, Jennifer M.

AU - Bloomston, Mark

AU - Bekaii-Saab, Tanios

AU - Guttridge, Denis C.

AU - Lesinski, Gregory B.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Involuntary weight loss, a part of the cachexia syndrome, is a debilitating comorbidity of cancer and currently has no treatment options. Results from a recent clinical trial at our institution showed that biliary tract cancer patients treated with a MEK inhibitor exhibited poor tumor responses but surprisingly gained weight and increased their skeletal muscle mass. This implied that MEKinhibition might be anticachectic. To test this potential effect of MEK inhibition, we utilized the established Colon-26 model of cancer cachexia and the MEK1/2 inhibitor MEK162. Results showed that MEK inhibition effectively prevented muscle wasting. Importantly, MEK162 retained its ability to spare muscle loss even in mice bearing a Colon-26 clone resistant to the MEK inhibitor, demonstrating that the effects of blocking MEK are at least in part independent of the tumor. Because single-agent MEK inhibitors have been limited as a first-line targeted therapy due to compensatory activation of other oncogenic signaling pathways, we combined MEK162 with the PI3K/Akt inhibitor buparlisib. Results showed that this combinatorial treatment significantly reduced tumor growth due to a direct activity on Colon-26 tumor cells in vitro and in vivo, while also preserving skeletal muscle mass. Together, our results suggest that as a monotherapy, MEK inhibition preserves muscle mass, but when combined with a PI3K/ Akt inhibitor exhibits potent antitumor activity. Thus, combinatorial therapy might serve as a new approach for the treatment of cancer cachexia.

AB - Involuntary weight loss, a part of the cachexia syndrome, is a debilitating comorbidity of cancer and currently has no treatment options. Results from a recent clinical trial at our institution showed that biliary tract cancer patients treated with a MEK inhibitor exhibited poor tumor responses but surprisingly gained weight and increased their skeletal muscle mass. This implied that MEKinhibition might be anticachectic. To test this potential effect of MEK inhibition, we utilized the established Colon-26 model of cancer cachexia and the MEK1/2 inhibitor MEK162. Results showed that MEK inhibition effectively prevented muscle wasting. Importantly, MEK162 retained its ability to spare muscle loss even in mice bearing a Colon-26 clone resistant to the MEK inhibitor, demonstrating that the effects of blocking MEK are at least in part independent of the tumor. Because single-agent MEK inhibitors have been limited as a first-line targeted therapy due to compensatory activation of other oncogenic signaling pathways, we combined MEK162 with the PI3K/Akt inhibitor buparlisib. Results showed that this combinatorial treatment significantly reduced tumor growth due to a direct activity on Colon-26 tumor cells in vitro and in vivo, while also preserving skeletal muscle mass. Together, our results suggest that as a monotherapy, MEK inhibition preserves muscle mass, but when combined with a PI3K/ Akt inhibitor exhibits potent antitumor activity. Thus, combinatorial therapy might serve as a new approach for the treatment of cancer cachexia.

UR - http://www.scopus.com/inward/record.url?scp=85011649886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011649886&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-16-0337

DO - 10.1158/1535-7163.MCT-16-0337

M3 - Article

C2 - 27811010

AN - SCOPUS:85011649886

VL - 16

SP - 344

EP - 356

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -